Off-label medication use in frontotemporal dementia

Bei Hu, Leslie Ross, John Neuhaus, David S Knopman, Joel Kramer, Bradley F Boeve, Richard John Caselli, Neill R Graff Radford, Mario F. Mendez, Bruce L. Miller, Adam L. Boxer

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective: There are no Food and Drug Administration (FDA)-approved medications indicated for the treatment of frontotemporal dementia (FTD). We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics. Methods: Medication and demographic data from the Alzheimergs Disease Research Centers of California (ARCC) and a multicenter FTD natural history study (NHS) data set were compared in bvFTD and Alzheimergs disease (AD), and effects of demographic variables were assessed using logistic regression. Results: Overall, the percentage of patients taking one or more FDA-approved AD or psychiatric medications was similar in bvFTD and AD; however, after controlling for demographic variables, acetylcholinesterase inhibitor (AChI) use was less common in bvFTD, whereas memantine use remained similar in the 2 groups. Conclusions: Despite lack of evidence for efficacy, the use of AChIs and memantine is common in bvFTD. Clinical trials should be pursued to determine the optimal therapeutic interventions for bvFTD.

Original languageEnglish (US)
Pages (from-to)128-133
Number of pages6
JournalAmerican Journal of Alzheimer's Disease and other Dementias
Volume25
Issue number2
DOIs
StatePublished - Mar 2010

Fingerprint

Off-Label Use
Frontotemporal Dementia
Memantine
Demography
United States Food and Drug Administration
Cholinesterase Inhibitors
Natural History
Psychiatry
Dementia
Logistic Models
Clinical Trials
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • Alzheimergs disease
  • Antipsychotic agents
  • Donepezil
  • Frontotemporal dementia
  • Galantamine
  • Memantine
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Off-label medication use in frontotemporal dementia. / Hu, Bei; Ross, Leslie; Neuhaus, John; Knopman, David S; Kramer, Joel; Boeve, Bradley F; Caselli, Richard John; Graff Radford, Neill R; Mendez, Mario F.; Miller, Bruce L.; Boxer, Adam L.

In: American Journal of Alzheimer's Disease and other Dementias, Vol. 25, No. 2, 03.2010, p. 128-133.

Research output: Contribution to journalArticle

Hu, Bei ; Ross, Leslie ; Neuhaus, John ; Knopman, David S ; Kramer, Joel ; Boeve, Bradley F ; Caselli, Richard John ; Graff Radford, Neill R ; Mendez, Mario F. ; Miller, Bruce L. ; Boxer, Adam L. / Off-label medication use in frontotemporal dementia. In: American Journal of Alzheimer's Disease and other Dementias. 2010 ; Vol. 25, No. 2. pp. 128-133.
@article{e5124ca687a24c768217f758ab1bddbb,
title = "Off-label medication use in frontotemporal dementia",
abstract = "Objective: There are no Food and Drug Administration (FDA)-approved medications indicated for the treatment of frontotemporal dementia (FTD). We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics. Methods: Medication and demographic data from the Alzheimergs Disease Research Centers of California (ARCC) and a multicenter FTD natural history study (NHS) data set were compared in bvFTD and Alzheimergs disease (AD), and effects of demographic variables were assessed using logistic regression. Results: Overall, the percentage of patients taking one or more FDA-approved AD or psychiatric medications was similar in bvFTD and AD; however, after controlling for demographic variables, acetylcholinesterase inhibitor (AChI) use was less common in bvFTD, whereas memantine use remained similar in the 2 groups. Conclusions: Despite lack of evidence for efficacy, the use of AChIs and memantine is common in bvFTD. Clinical trials should be pursued to determine the optimal therapeutic interventions for bvFTD.",
keywords = "Alzheimergs disease, Antipsychotic agents, Donepezil, Frontotemporal dementia, Galantamine, Memantine, Treatment",
author = "Bei Hu and Leslie Ross and John Neuhaus and Knopman, {David S} and Joel Kramer and Boeve, {Bradley F} and Caselli, {Richard John} and {Graff Radford}, {Neill R} and Mendez, {Mario F.} and Miller, {Bruce L.} and Boxer, {Adam L.}",
year = "2010",
month = "3",
doi = "10.1177/1533317509356692",
language = "English (US)",
volume = "25",
pages = "128--133",
journal = "American Journal of Alzheimer's Disease and other Dementias",
issn = "1533-3175",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Off-label medication use in frontotemporal dementia

AU - Hu, Bei

AU - Ross, Leslie

AU - Neuhaus, John

AU - Knopman, David S

AU - Kramer, Joel

AU - Boeve, Bradley F

AU - Caselli, Richard John

AU - Graff Radford, Neill R

AU - Mendez, Mario F.

AU - Miller, Bruce L.

AU - Boxer, Adam L.

PY - 2010/3

Y1 - 2010/3

N2 - Objective: There are no Food and Drug Administration (FDA)-approved medications indicated for the treatment of frontotemporal dementia (FTD). We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics. Methods: Medication and demographic data from the Alzheimergs Disease Research Centers of California (ARCC) and a multicenter FTD natural history study (NHS) data set were compared in bvFTD and Alzheimergs disease (AD), and effects of demographic variables were assessed using logistic regression. Results: Overall, the percentage of patients taking one or more FDA-approved AD or psychiatric medications was similar in bvFTD and AD; however, after controlling for demographic variables, acetylcholinesterase inhibitor (AChI) use was less common in bvFTD, whereas memantine use remained similar in the 2 groups. Conclusions: Despite lack of evidence for efficacy, the use of AChIs and memantine is common in bvFTD. Clinical trials should be pursued to determine the optimal therapeutic interventions for bvFTD.

AB - Objective: There are no Food and Drug Administration (FDA)-approved medications indicated for the treatment of frontotemporal dementia (FTD). We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics. Methods: Medication and demographic data from the Alzheimergs Disease Research Centers of California (ARCC) and a multicenter FTD natural history study (NHS) data set were compared in bvFTD and Alzheimergs disease (AD), and effects of demographic variables were assessed using logistic regression. Results: Overall, the percentage of patients taking one or more FDA-approved AD or psychiatric medications was similar in bvFTD and AD; however, after controlling for demographic variables, acetylcholinesterase inhibitor (AChI) use was less common in bvFTD, whereas memantine use remained similar in the 2 groups. Conclusions: Despite lack of evidence for efficacy, the use of AChIs and memantine is common in bvFTD. Clinical trials should be pursued to determine the optimal therapeutic interventions for bvFTD.

KW - Alzheimergs disease

KW - Antipsychotic agents

KW - Donepezil

KW - Frontotemporal dementia

KW - Galantamine

KW - Memantine

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=77749270419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749270419&partnerID=8YFLogxK

U2 - 10.1177/1533317509356692

DO - 10.1177/1533317509356692

M3 - Article

C2 - 20124256

AN - SCOPUS:77749270419

VL - 25

SP - 128

EP - 133

JO - American Journal of Alzheimer's Disease and other Dementias

JF - American Journal of Alzheimer's Disease and other Dementias

SN - 1533-3175

IS - 2

ER -